INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common form of dementia in the elderly population.
The disease is neuropathologically characterized by the presence of neurofibrillary tangles and senile or amyloid plaques in vulnerable brain regions, such as the cerebral cortex and hippocampus. Despite considerable efforts aimed to understand the molecular and cellular basis of AD, there are currently no effective treatments to cure it or to arrest its progression (De Felice and Ferreira, 2002) .
It is widely accepted that the β-amyloid peptide (Aβ), derived from proteolytic processing of the membrane-bound amyloid precursor protein (APP), plays a central role in the neuropathology of AD (Hardy and Selkoe, 2002 We have previously characterized a number of small molecule inhibitors of the oligomerization and fibrillization of Aβ, which potently protect hippocampal neurons against Aβ-induced neurotoxicity (De Felice et al., 2001 . Considering their moderately hydrophobic nature, we hypothesized that some of those compounds would be able to cross cell membranes and could also be effective in decreasing amyloid accumulation in intracellular compartments. Here, we show that treatment with low, non-toxic concentrations of 2,4-dinitrophenol, 3-nitrophenol and 4-anisidine decreases the intracellular accumulation of amyloid in vesicular bodies in the CTb cell line. These results suggest that these compounds could be used as leads for the development of inhibitors that target both extracellular and intracellular amyloid accumulation. Neuronal survival was determined using the Live/Dead kit (Molecular Probes, Inc., Eugene, OR) following manufacturer's instructions. Cells were examined and counted on a Nikon Eclipse TE300 microscope. Live cells were identified by green calcein fluorescence, while dead cells were identified by red etidium fluorescence. Two to five random fields were chosen per coverslip, and about 500 cells were counted on each field. Three independent assays were performed (2-4 cover slips per assay). Viabilities are expressed as percentage of cell survival (means ± SEM). Statistical significances were evaluated using unpaired Student's t-test.
For Congo Red (CR) staining, CNh and CTb cells were differentiated for five days and were then treated with 20 μM 2,4-DNP, 3-NP or 4-AA for 48 hours, as described above. CR staining of intracellular amyloidcontaining vesicular bodies was performed following a slight modification of the protocol described in (Puchtler and Sweat, 1965 (Fig. 1C) , caused no alterations in intracellular calcium concentration in CTb cells (Fig. 3) .
It remains to be elucidated whether the compounds investigated here disaggregate amyloid aggregates in the cytoplasmic vesicular bodies, interfere with intracellular formation and accumulation of APP, or both. Considering the incubation time of the cells with the compounds (48 h), it is possible that they interfere with one or more steps of amyloid processing pathways. However, the compounds tested here have been shown to In the present work, we have not determined which fragments of APP accumulated in CR-positive vesicular bodies. Western blot analysis of cell lysates Recordings were obtained from 10-15 individual cells per cover slip (three cover slips per experiment) and were converted to intracellular calcium concentrations using a calibration curve, as described in "Methods". Data are means ± SEM of three independent experiments. Statistical significances were evaluated using unpaired Student's t-test. * p < 0.02 compared to the respective untreated control.
revealed an APP fragment of about 98 kDa, which is immunoreactive to a commercial antibody against Aβ 1-40/42 (data not shown), indicating that it encompasses the Aβ sequence. This suggests that the intracellular vesicular bodies probably contain aggregates of an amyloidogenic nature that are positively stained with CR.
Regardless of the precise nature of the amyloid species present, the results presented here show that the smallmolecule compounds tested were capable of reducing the percentage of CTb cells containing CR-positive vesicular bodies.
CONCLUSION
Taken together with previous results (De Felice et al., 2001 , the data presented here suggest that 2,4-DNP, 3-NP and 4-AN may be useful lead compounds for the development of drugs that target both extracellular deposition and intracellular accumulation of amyloid fragments.
